Hearing loss due to concurrent daily low-dose cisplatin chemoradiation for locally advanced head and neck cancer

Radiotherapy and Oncology

Volumn 89, Issue 1, 2008, Pages 38-43

  Zuur, Charlotte L ^a   Simis, Yvonne J W ^b   Verkaik, Roxanna S ^c   Schornagel, Jan H ^c   Balm, Alfons J M ^b,c   Dreschler, Wouter A ^b   Rasch, Coen R N ^c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

Chemoradiation; Cisplatin; Head and neck cancer; Hearing loss; Radiotherapy

Indexed keywords

CISPLATIN;

ADULT; AIR CONDUCTION; ARTICLE; AUDIOGRAPHY; AUDIOMETRY; BONE CONDUCTION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HEAD AND NECK CANCER; HEARING LOSS; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY;

AUDIOMETRY; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; HEAD AND NECK NEOPLASMS; HEARING LOSS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RADIOTHERAPY; RISK FACTORS; STATISTICS, NONPARAMETRIC;

EID: 53049084919     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2008.06.003     Document Type: Article

References (31)

1. Sankaranarayanan R., Masuyer E., Swaminathan R., Ferlay J., and Whelan S. Head and neck cancer: a global perspective on epidemiology and prognosis. Anticancer Res 18 (1998) 4779-4786
2. Pignon J.P., Bourhis J., Domenge C., et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet 355 (2000) 949-955
3. Adelstein D.J., Li Y., Adams G.L., et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21 (2003) 92-98
4. Cooper J.S., Pajak T.F., Forastiere A.A., et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Eng J Med 350 (2004) 1937-1944
5. Vega de la F.A., Vera Garcia R., Dominguez D., et al. Hyperfractionated radiotherapy and concomitant cisplatin for locally advanced laryngeal and hypopharyngeal carcinomas. Am J Clin Oncol 26 (2003) 550-557
6. Lau H., Brar S., Hao D., MacKinnon J., Yee D., and Gluck S. Concomitant low-dose cisplatin and three-dimensional conformal radiotherapy for locally advanced squamous cell carcinoma of the head and neck: analysis of survival and toxicity. Head Neck 28 (2006) 189-196
7. Beckmann G.K., Hoppe F., Pfeundner L., and Flentje M.P. Hyperfractionated accelerated radiotherapy in combination with weekly cisplatin for locally advanced head and neck cancer. Head Neck 27 (2005) 36-43
8. Jeremic B., Milicic B., Dagovic A., Vaskovic Z., and Tadic L. Radiation therapy with or without concurrent low-dose daily cisplatin chemotherapy in locally advanced, nonmetastatic squamous cell carcinoma of the head and neck. J Clin Oncol 22 (2004) 3540-3548
9. Bartelink H., Bogaert van den W., Horiot J.C., Jager J., and Glabbeke van M. Concomitant cisplatin and radiotherapy in a conventional and modified fractionation schedule in locally advanced head and neck cancer: a randomised phase II EORTC trial. Eur J Cancer 38 (2002) 667-673
10. Aguilar-Markulis N.L., Beckly S., Priore R., and Mettlin C. Auditory effects of long-term cis-dichlorodiammineplatinum II therapy in genitourinary cancer patients. J Surg Oncol 16 (1981) 111-123
11. Schweitzer V.G. Cisplatin-induced ototoxicity: the effect of pigmentation and inhibitory agents. Laryngoscope 103 (1993) 1-52
12. Anteunis L.J.C., Wanders S.L., Hendriks J.J.T., et al. A prospective longitudinal study on radiation-induced hearing loss. Am J Surg 168 (1994) 408-411
13. Ho W.K., Wei W.I., Kwong D.L.W., et al. Long-term sensorineural hearing deficit following radiotherapy in patients suffering from nasopharyngeal carcinoma: a prospective study. Head Neck 21 (1999) 547-553
14. Kwong D.L.W., Wei W.I., Sham J.S.T., et al. Sensorineural hearing loss in patients treated for nasopharyngeal carcinoma: a prospective study of the effect of radiation and cisplatin treatment. Int J Rad Oncol Biol Physiol 36 (1996) 281-289
15. Raaijmakers E., and Engelen A.M. Is sensorineural hearing loss a possible side effect of nasopharyngeal and parotid irradiation? A systematic review of the literature. Radiother Oncol 65 (2002) 1-7
16. Oh Y.T., Kim C.H., Choi J.H., et al. Sensory neural hearing loss after concurrent cisplatin and radiation therapy for nasopharyngeal carcinoma. Radiother Oncol 72 (2004) 79-82
17. Palazzi M.P., Guzzo M., Tomatis S., et al. Improved outcome of nasopharyngeal carcinoma treated with conventional radiotherapy. Int J Rad Oncol Biol Physiol 60 (2004) 1451-1458
18. Wang L.F., Kuo W.R., Ho K.Y., et al. A long-term study on hearing status in patients with nasopharyngeal carcinoma after radiotherapy. Otol Neurotol 25 (2004) 168-173
19. Pan C.C., Eisbruch A., Lee J.S., et al. Prospective study of inner ear radiation dose and hearing loss in head-and-neck cancer patients. Int J Rad Oncol Biol Physiol 61 (2005) 1393-1402
20. Zuur C.L., Simis Y.J.W., Lansdaal P.E.M., et al. Ototoxicity in a randomized phase III trial of intra-arterial versus intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer; a multivariate analysis. J Clin Oncol 25 (2007) 3759-3765
21. Zuur C.L., Simis Y.J.W., Lansdaal P.E.M., et al. Audiometric patterns in ototoxicity of intra-arterial cisplatin chemoradiation in patients with locally advanced head and neck cancer. Audiol Neurotol 11 (2006) 318-330
22. Zuur C.L., Simis Y.J.W., Lansdaal P.E.M., et al. Risk factors of ototoxicity after cisplatin-based chemo-irradiation in patients with locally advanced head-and-neck cancer: a multivariate analysis. Int J Radiat Oncol Biol Phys 68 (2007) 1320-1325
23. CRN Rasch, AJM Balm, JH Schornagel, et al. Intra-arterial versus intravenous chemoradiation for advanced head and neck cancer, early results of a multi-institutional trial. ASTRO, 2006 (Abstract).
24. Hoebers F.J.P., Heemsbergen W., Balm A.J.M., Zanten van M., Schornagel J.H., and Rasch C.R.N. Concurrent chemoradiation with daily low dose cisplatin for advanced stage head and neck carcinoma. Radiother Oncol 85 (2007) 42-47
25. Cancer Therapy Evaluation Programm, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS, March 31, 2003. Available from: http://ctep.cancer.gov. Publ. date: December 12, 2003.
26. Dreschler W.A., vd Hulst R.J., Tange R.A., and Urbanus N.A. The role of high-frequency audiometry in early detection of ototoxicity. Audiol 24 (1985) 387-395
27. Zuur CL, Simis YJ, Lamers EA, Hart AA, Dreschler WA, Balm AJ, Rasch CR. Risk factors for hearing loss in head-and-neck cancer patients treated with Intensity-Modulated Radiation Therapy. Currently under review.
28. Johannesen T.B., Rasmussen K., Winther F.O., Halvorsen U., and Lote K. Late radiation effects on hearing, vestibular function, and taste in brain tumor patients. Int J Radiat Oncol Biol Phys 53 (2002) 86-90
29. Grau C., Moller K., Overgaard M., Overgaard J., and Elbrond O. Sensori-neural hearing loss in patients treated with irradiation for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 21 (1991) 723-728
30. Vermorken J.B., Kapteijn T.S., Hart A.A., and Pinedo H.M. Ototoxicity of cis-diamminedichloroplatinum (II): influence of dose, schedule and mode of administration. Eur J Cancer Clin Oncol 19 (1983) 53-58
31. Laurell G., and Bagger-Sjöbäck D. Dose-dependent inner ear changes after i.v. administration of cisplatin. J Otolaryngol 20 (1991) 158-167